State Street SPDR S&P Pharmaceuticals ETF
XPH
71 hedge funds and large institutions have $259M invested in State Street SPDR S&P Pharmaceuticals ETF in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 14 closing their positions.
12.22% more ownership
Funds ownership: 40.43% → 52.65% (+12%)
4% less capital invested
Capital invested by funds: $271M → $259M (-$11.5M)
7% less funds holding
Funds holding: 76 → 71 (-5)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
33% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 24
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$61.7M |
| 2 |
Barclays
London,
United Kingdom
|
+$27.5M |
| 3 |
Nomura Asset Management
Tokyo,
Japan
|
+$1.41M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$896K |
| 5 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
+$700K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$14.9M |
| 2 |
LPL Financial
San Diego,
California
|
-$5.64M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.75M |
| 4 |
EC
Estate Counselors
Thiensville,
Wisconsin
|
-$3.3M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.27M |
XPH Hedge Fund Activity: Q1 2016 in Review
71 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2016, worth a combined $259M — down 4.2% from $271M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of XPH and 10 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 16 added.
The largest buyer was Goldman Sachs, adding an estimated $61.7M. The largest seller was Morgan Stanley, cutting an estimated $14.9M.
- 71 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2016, down from 76 in Q4 2015.
- Funds reported $259M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2016, down 4.2% quarter-over-quarter.
- 10 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2016 and 14 closed out, a net change of -4 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2016 was Goldman Sachs, an estimated $61.7M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2016 was Morgan Stanley, an estimated $14.9M sold.
Based on aggregated 13F filings for Q1 2016.